Genomics-enabled drug repositioning and repurposing: Insights from an IOM roundtable activity

JAMA

Volumn 311, Issue 20, 2014, Pages 2063-2064

  Power, Aidan ^a   Berger, Adam C ^b   Ginsburg, Geoffrey S ^c  

^a PFIZER INC   (United States)

^b Institute of Medicine   (United States)

^c DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE;

BIOINFORMATICS; DRUG COST; DRUG INDICATION; DRUG INDUSTRY; DRUG REPOSITIONING; DRUG RESEARCH; FUNDING; GENETIC ASSOCIATION; GENOMICS; INTERDISCIPLINARY RESEARCH; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SHORT SURVEY;

DRUG INDUSTRY; DRUG REPOSITIONING; GENOMICS; INSTITUTE OF MEDICINE (U.S.); RESEARCH SUPPORT AS TOPIC; TRANSLATIONAL MEDICAL RESEARCH; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84901626678     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.3002     Document Type: Short Survey

References (8)

1. Novac N. Challenges and opportunities of drug repositioning. Trends Pharmacol Sci. 2013;34(5):267-272.
2. Institute of Medicine. Drug repurposing and repositioning. http://www.iom.edu/Reports/2014/Drug-Repurposing-and-Repositioning. Accessed May 23, 2014.
3. Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human genetics. Nat Rev Drug Discov. 2013;12(8):581-594.
4. Denny JC, Bastarache L, Ritchie MD, et al. Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat Biotechnol. 2013;31(12):1102-1110.
5. National Center for Advancing Translational Sciences. New therapeutic uses: 2013 project awards. http://www.ncats.nih.gov/research/reengineering/ rescue-repurpose/therapeutic-uses/projects-2013.html. Accessed March 4, 2014.
6. Medical Research Council. Alzheimer's, cancer and rare disease research to benefit from landmark MRC-AstraZeneca compound collaboration. http://www.mrc.ac.uk/Newspublications/News/Archive/MRC008918. Accessed March 4, 2014.
7. US Food and Drug Administration; Center for Drug Evaluation and Research. Novel new drugs: 2013 summary. http://www.fda.gov/downloads/drugs/ developmentapprovalprocess/druginnovation/ucm381803.pdf. Accessed March 4, 2014.
8. US Food and Drug Administration. A valuable resource for drug developers: the Rare Disease Repurposing Database. http://www.fda.gov/ForIndustry/ DevelopingProductsforRareDiseasesConditions/ HowtoapplyforOrphanProductDesignation/ucm216147.htm. Accessed March 4, 2014.